Zydus Lifesci.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE010B01027
  • NSEID: ZYDUSLIFE
  • BSEID: 532321
INR
1,195.05
-4.95 (-0.41%)
BSENSE

Nov 20

BSE+NSE Vol: 7.94 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Mankind Pharma
Divi's Lab.
Laurus Labs
Aurobindo Pharma
Zydus Lifesci.
Torrent Pharma
Dr Reddy's Labs
Glenmark Pharma
Cipla
Lupin
Sun Pharma.Inds.
Why is Zydus Lifesciences Ltd ?
1
Low Debt Company with Strong Long Term Fundamental Strength
  • Healthy long term growth as Net Sales has grown by an annual rate of 15.02% and Operating profit at 17.74%
  • Company has a low Debt to Equity ratio (avg) at 0.10 times
  • The company has been able to generate a Return on Equity (avg) of 17.09% signifying high profitability per unit of shareholders funds
2
The company has declared negative results for the last 2 consecutive quarters
  • PAT(Q) At Rs 924.54 cr has Fallen at -28.0%
  • OPERATING CF(Y) Lowest at Rs 2,116.60 Cr
  • ROCE(HY) Lowest at 16.13%
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 17-Nov-26
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and OBV
4
With ROCE of 16.9, it has a Fair valuation with a 3.5 Enterprise value to Capital Employed
  • The stock is trading at a fair value compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 28.83%, its profits have fallen by -10.1%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Zydus Lifesci. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zydus Lifesci. for you?

Low Risk, High Return

Absolute
Risk Adjusted
Volatility
Zydus Lifesci.
28.83%
1.17
24.71%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
15.02%
EBIT Growth (5y)
17.74%
EBIT to Interest (avg)
29.20
Debt to EBITDA (avg)
0.75
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.84
Tax Ratio
24.79%
Dividend Payout Ratio
2.00%
Pledged Shares
0
Institutional Holding
18.33%
ROCE (avg)
21.53%
ROE (avg)
17.09%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
26
Industry P/E
40
Price to Book Value
4.29
EV to EBIT
20.66
EV to EBITDA
15.61
EV to Capital Employed
3.50
EV to Sales
4.21
PEG Ratio
NA
Dividend Yield
0.08%
ROCE (Latest)
16.93%
ROE (Latest)
16.52%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
DEBTORS TURNOVER RATIO(HY)

Highest at 6.80 times

NET SALES(Q)

At Rs 7,909.60 cr has Grown at 29.17%

-28What is not working for the Company
PAT(Q)

At Rs 924.54 cr has Fallen at -28.0%

OPERATING CF(Y)

Lowest at Rs 2,116.60 Cr

ROCE(HY)

Lowest at 16.13%

DEBT-EQUITY RATIO(HY)

Highest at 0.50 times

OPERATING PROFIT TO INTEREST (Q)

Lowest at 10.13 times

DPR(Y)

Lowest at 2.00%

INTEREST(Q)

Highest at Rs 187.00 cr

OPERATING PROFIT TO NET SALES (Q)

Lowest at 23.95%

PBT LESS OI(Q)

Lowest at Rs 1,130.50 cr.

EPS(Q)

Lowest at Rs 9.27

Loading Valuation Snapshot...
Here's what is working for Zydus Lifesci.
Net Sales - Quarterly
At Rs 7,909.60 cr has Grown at 29.17%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Debtors Turnover Ratio- Half Yearly
Highest at 6.80 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Zydus Lifesci.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1,130.50 cr has Fallen at -29.90%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 924.54 cr has Fallen at -28.0%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Operating Profit to Interest - Quarterly
Lowest at 10.13 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly
Highest at 0.50 times and Grown
each half year in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Operating Cash Flow - Annually
Lowest at Rs 2,116.60 Cr
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Interest - Quarterly
Highest at Rs 187.00 cr
in the last five quarters and Increased by 19.87 % (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Operating Profit Margin - Quarterly
Lowest at 23.95%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs 1,130.50 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Lowest at Rs 9.27
in the last five quarters
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Dividend Payout Ratio (DPR) - Annually
Lowest at 2.00%
in the last five years
MOJO Watch
Company is distributing lower proportion of profits generated as dividend

DPR (%)